血液α-Synuclein将帕金森病与勒维体痴呆症分开
George T Kannarkat1, Rebecca Zack1, R Tyler Skrinak1
1Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Annals of neurology
|June 16, 2025
概括
血中的错误折叠的α-synuclein (aSyn) 菌株,而不是CSF,可能会影响莱维体疾病 (LBD) 的进展和认知. 血aSyn菌株与大脑形式不同,可能起源于中枢神经系统之外.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 病理学 病理学 病理学
背景情况:
- 错误折叠的α-synuclein (aSyn) 聚合定义了勒维体疾病 (LBD),包括帕金森病 (PD) 和勒维体痴呆症 (DLB).
- 提出了不同的aSyn"菌株" (形状),但缺乏将PD与DLB区分开来的生物标志物.
- 这项研究调查了人体组织和液体中的特定aSyn菌株.
研究的目的:
- 使用新的α-synuclein (aSyn) 菌株特异性生物标志物区分帕金森病 (PD) 和患有勒维体痴呆症 (DLB).
- 研究不同aSyn菌株在血和脑脊液 (CSF) 中的存在和潜在作用.
- 探索血aSyn菌株与PD患者认知衰退之间的相关性.
主要方法:
- 使用单克隆抗体向两种不同的aSyn物种 (A和B菌株).
- 分析了使用ELISA,西斑和免疫组织化学的LBD和无LBD个体的人类大脑组织,CSF和血.
- 采用种子放大试验 (SAA) 和细胞模型来表征免疫沉的aSyn物种.
主要成果:
- 在两个队列中,aSyn菌株A和B的血水平在PD患者中高于DLB患者.
- 较低的aSyn A菌株血水平与PD中更快的认知衰退相关.
- 在CSF中无法检测到aSyn菌株,大脑和血水平没有相关性;血aSyn菌株可以播种纤维化和细胞内含.
结论:
- 流通的血aSyn菌株可能会影响LBD的临床表现,特别是认知功能.
- 这些aSyn物种在血中的丰富,但不是CSF,表明一种脑外起源.
- 基于等离子体的aSyn菌株检测为LBD生物标志物开发和理解疾病异质性提供了潜在的途径.
更多相关视频
10:03Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
Published on: August 16, 2020
10.8K
12:01Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein
Published on: May 30, 2015
10.8K
相关概念视频
Neural Regulation
40.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.4K
Parkinson's Disease: Overview
723
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
723
Alzheimer's Disease: Overview
686
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
686
Amyloid Fibrils
9.9K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.9K
Dementia
182
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
182
